Cambridge Isotope Laboratories, Inc’s Post

I am delighted to share our recent publication on the molecular investigation of Klebsiella pneumoniae at a neonatal intensive care unit of a secondary care maternal and pediatric hospital in Nepal. We document the occurrence of K. pneumoniae strains producing beta-lactamases, mostly extended-spectrum beta-lactamases, and harbouring accessory mechanisms of iron acquisition (the most prominent being yersiniabactin siderophore). Does this overlap between the mechanisms of drug resistance and accessory virulence hold any clinical significance? Also, we report two potential hypervirulent Klebsiella pneumoniae (HvKp) strains. Keeping in mind the high rates of mortality associated with HvKp invasive infections, are the healthcare settings, especially high-risk settings, in resource-limited settings equipped with laboratory infrastructures to promptly detect these strains of concern needed to limit their further spread? #antimicrobialresistance #Klebsiellapneumoniae #neonates #LMIC

Learn more about MCA Doppler scans from our "MCA May" series with The TAPS Support Foundation. Why are MCA dopplers so important? Because they are the most reliable, noninvasive way to detect fetal anemia. The Allo Hope Foundation and TAPS Support joined forces to talk about MCA Doppler Ultrasound and why it is so important in the monitoring of both of our diseases. #AlloHopeFoundation #TAPSSupport #FetalAnemia #MCADoppler #HDFN #maternalalloimmunization #tapsawareness

Spinal muscular atrophy (SMA) can have a devastating impact on the babies and families affected. Without treatment, it is the leading genetic cause of infant death in the UK; early detection and intervention on the other hand can drastically change outcomes. Despite this, SMA is not currently included within the Newborn Screening Programme in the UK. Developed with experts from across the SMA and rare disease communities, the Every Moment Matters report explores the potential benefits newborn screening for SMA could bring, both to the individuals and families affected, and to the UK's wider rare disease and life sciences ambitions. Read the report and recommendations here: https://lnkd.in/eznXsf9R  #NovartisOK

Diagnosing hydrops fetalis, a condition characterized by abnormal fluid accumulation in multiple tissues or body cavities, is a significant challenge in maternal-fetal medicine. The genesis of hydrops fetalis is diverse, including immune- and nonimmune-mediated factors. Immune hydrops fetalis, or erythroblastosis fetalis, is primarily caused by alloimmunization, particularly in RhD-negative mothers with RhD-positive fetuses, causing hemolytic disease of the fetus and newborn (HDFN). The progressive destruction of red blood cells leads to severe fetal anemia. Read more: https://brnw.ch/21wGklW #RareDisease

Catheter ablation for AF was associated with reduced risk of HF events in patients with HFrEF but had limited or no benefit in HFpEF. https://ja.ma/4eiGQjk

POSTCOVID-19 WAR era, (>May-2024) Pre- and Posttransfusion management QMS, QC, and QAs of certain isolated blood components and AI-related bias-based (re)actions can increase the risk of crosscontamination between donors and recipients/patients, however.

A very useful State-of-Art review paper on how to manage patients with heart failure with preserved EF (HFpEF). The first step is confirming the diagnosis of HFpEF and excluding alternatives. Management if HFpEF should include aggressive managent of congestion, addressing comorbidities, and initiation of evidence-based medical treatment (GDMT) which would include: SGLT2 inhibitors for most patients which is now considered the standard of care, and addition of an ARNI and/or MRA may be appropriate for many. And it is important as well to recommend Exercise and lifestyle modification to facilitate weight reduction. #heartfailure #GDMT

Incredibly important manuscript on the need for universal screening for congenital hyperinsulinism. Please read this post, the Journal of Clinical Medicine article, and my blog about the article, all in the post from Congenital Hyperinsulinism International: "I am just thrilled there are neonatologists and perinatologists who, through their publication, are communicating to others in their field about this key issue. These physicians recognize and have now published vital information about how not performing a very simple and inexpensive test leads to lifelong disability for a significant portion of babies born with HI." You find my analysis as well as the paper at https://lnkd.in/eR5hBZ3i

Since September is Sickle Cell Awareness Month, we would like to highlight one of the articles " Characterisation of medical conditions of children with sickle cell disease in the USA: findings from the 2007–2018 National Health Interview Survey (NHIS)" published by the members of the Implementing Sustainable Evidence-based Interventions through Engagement (ISEE) Lab at New York University (NYU) in 2023. Read the full article at Doi:10.1136/bmjopen-2022-069075 Did you know? The ISEE Lab at NYU has a section on Implementing Evidence-based Interventions for Sickle Cell Disease. The goal is to evaluate evidence-based interventions and strategies for Sickle Cell Disease management in low-resource settings. It aims to take a context specific approach in its implementation strategies and understand the factors that influence the adoption of SCD interventions by certain communities and not by others. For more information on the lab's work on Sickle Cell Disease, please visit its website https://lnkd.in/eQfFc2XK #implementationscience #sicklecellawareness #publichealth #isee #nyu

The maternal fetal space is a critical area of medicine, and one where there is a significant need for available treatment options. Hemolytic disease of the fetus and newborn (HDFN) and fetal neonatal alloimmune thrombocytopenia (FNAIT) are rare, alloimmune diseases that lack approved therapies targeting their underlying causes. To meet this need, further research is needed to better understand these diseases, identify at-risk pregnancies, and ensure therapies are safe for pregnant people, fetuses, and newborns.    I am proud to be on the grounds at The Fetal Medicine Foundation 2024 conference with #MyCompany, Johnson & Johnson Innovative Medicine, as we demonstrate our unwavering commitment to advancing maternal fetal medicine for the patients and families who need it most.    #JNJImmunology #MaternalHealth